We have a global team of experienced veterinarians that have now treated many thousands of cases. Please feel free to contact us to answer any questions on case selection and management, or the clinical application of Arthramid® Vet.

FAQ

Case Selection & Management

Product Description

Arthramid® Vet is used to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA).

Arthramid® Vet is a biocompatible, non-absorbable, non-pyrogenic, neuro-innocuous injectable 2.5% cross-linked polyacrylamide hydrogel for intra-articular injection in animals. Arthramid® Vet consists of approximately 2.5% cross-linked polyacrylamide and 97.5% water for injection. The hydrogel is supplied in a sterile pre-filled 1 mL syringe sealed with a Luer lock fitting.

Arthramid® Vet hydrogel acts as a dynamic tissue scaffold that increases the elasticity and load transfer capacity of the joint, restoring the joint to healthy function.

Case Selection

Understanding the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is essential.

Arthritis describes inflammation of a joint and can occur after single or repetitive episodes of trauma. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis (OA). Sub-chondral bone injury also plays a role.

These pathological conditions are ‘a group of overlapping distinct diseases which may have different aetiologies, but with similar biologic, morphologic, and clinical outcomes.’

Although conventional concepts of OA emphasise the direct and predominant involvement of cartilage and bone in OA development, it is increasingly recognised that the synovium also contributes to the central pathophysiological event of cartilage matrix depletion.

Cases suitable for treatment with Arthramid® Vet are those in which lameness is localised to the joint by clinical examination and intra-articular analgesia,+/- radiography, ultrasound, MRI, CT and/or Scintigraphy. Conditions that respond to treatment with Arthramid® Vet include acute and chronic synovitis, capsulitis, meniscal tears, OA, and subchondral bone cysts. It is essential that anamnesis of data of ongoing infection, concomitant medication, surgery or potential fracture is reviewed prior to injection to prevent possible infections or use of the product for conditions other than for which it is indicated.

Case Management

Animals should be rested for 48 hours immediately after treatment. After this time the animal can return to exercise compared to its level of comfort.

Clinical studies show that tissue integration and subsequent augmentation of the joint capsule takes between 2 and 4 weeks to occur, although a response to treatment can be seen earlier than that in some cases.

Animals typically show a gradual reduction in lameness during the first week after treatment and a concurrent reduction in reaction to passive flexion. This continues to improve over the ensuing 2 to 3 weeks. By 4 weeks no further improvement is expected. Re-examination at 4 weeks is therefore indicated to either administer a second dose in those that have only partially responded or to reassess accuracy of the diagnosis.

It is important for owners to understand the time lag for a treatment effect to be seen as this contrasts with conventional therapies. In this respect and due to its long lasting effect it may also be prudent to consider treating the animal during periods of reduced exercise demands or early on in the animals training programme.

Product Storage

Arthramid® Vet must be stored below 25°C (air conditioning) protected from direct sunlight. Do not freeze. Do not store unsealed syringes for later use.

Information To The Animal Owner

The owner of the animal should be informed about the indications, expected results, contraindications, precautions, warnings, and potential complications. The owner of the animal should be advised that in the case of post-application complications, the veterinarian who performed the Arthramid® Vet injections should be contacted immediately for necessary treatment.

Arthramid® Vet User Guide

Veterinarians: Get our treatment guide for dosage, mode of action, case selection, case management and post injection care.

GET THE USER GUIDE
User Guide Download
This field is for validation purposes and should be left unchanged.

Testimonials

Dr Florent David

EQUINE VETERINARY MEDICAL CENTRE

AL SHAQAB STREET, DOHA, QATAR

Arthramid Vet should be in the therapeutic toolbox of any equine veterinarian. ”

READ MORE
Dr Florent David

EQUINE VETERINARY MEDICAL CENTRE

AL SHAQAB STREET, DOHA, QATAR

I have been using Arthramid Vet for five years. I see lame horses that I qualify as “non-responders”. The diagnosis/localisation of pain is accurate on those cases, but they do not respond to rest, and corticosteroids +/- HA intrasynovial. These represent my biggest challenge. Arthramid Vet is often of great help on those cases in association with orthopaedic shoeing, magnetic diathermy and a revisited exercise program to regain and maintain soundness.

The second set of cases that represent a challenge are horses presented with poor performance. They are not genuinely lame, but several sites in their body including joints show signs of wear and tear. This accumulation of stress is associated with the athletic activity they perform and also to some individual predispositions to injury (poor conformation, overweight, lack of repair capacities). On these cases, Arthramid Vet for its long duration of action can help.

The third group of horses I see as a challenge are diagnosed with soft tissue injuries within synovial structures (tendon sheath, bursa or joint). In general, the body responds poorly to healing those lesions. It is still unclear to me if Arthramid Vet can help to return some of these horses to soundness when unsatisfactory healing of intrasynovial soft tissue has occurred.

Arthramid Vet is a very potent and very safe drug to use, and I recommend it to my clients and other vets. Arthramid Vet should be in the therapeutic toolbox of any equine veterinarian. I see Arthramid Vet as a solution with great potential, and more work is needed to refine its use.

Arthramid Vet should be in the therapeutic toolbox of any equine veterinarian. ”

Dr Emma Wood

VETERINARIAN

On his non gallop days he would complete 4000m of cantering daily, this is a lot of miles on his joints and I do not believe we could have kept him sound without the use of Arthramid.”

READ MORE
Dr Emma Wood

VETERINARIAN

We treated Sound (front fetlocks) in December 2019 which correlates with his turn around in form in February and March 2020, he was again treated in June 2020 (front fetlocks) and July 2020 (left front tendon sheath) after a flare of synovitis. Within 3 weeks both fetlocks and tendon sheath were tight and his action terrific. He went on to run 2nd in the Lexus and win the G2 Zipping Classic (5+ months after injection). As an 8yo stallion Sound tends to hold condition and to reach peak fitness he underwent a tough spring training campaign. On his non gallop days he would complete 4000m of cantering daily, this is a lot of miles on his joints and I do not believe we could have kept him sound without the use of Arthramid. Not only did he perform well but he maintained soundness and his action improved throughout the preparation.

On his non gallop days he would complete 4000m of cantering daily, this is a lot of miles on his joints and I do not believe we could have kept him sound without the use of Arthramid.”

ALL TESTIMONIALS

Interested in talking to us and learning more?

Schedule a time with one of our experts
BOOK NOW